All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
26 results for "Cancer" and "Gynecologic Cancers" and "Multiple Myeloma"
Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma.
Protocol No
TAKEDA-TAK-981-1503
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients with Advanced Hematologic Malignancies
To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of oral LOXO-338 in patients with previously treated advanced hematologic malignancies.
Protocol No
LOXO-BCL-20001
Master Protocol for the phase 1 Study of Cell therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, including Long-term Safety Follow-up
Arcellx-ACLX-001-ddBCMA-MM-Master Protocol
Protocol No
ARCELLX-ACLX-001-DDBCMA
Sub Category
Open label, multi-center, phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma
Clinical Trial to Evaluate CT053 in Patients with R/R-MM (LUMMICAR Study 2)
Protocol No
CARSGEN-CT053-MM-02
Sub Category
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory MM
Protocol No
IIT-DHAKAL-IMPEDE-SGZ-12356
Sub Category
A Phase I Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with r/r MM
Protocol No
FATE-FT576-101-MM
Sub Category
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
JNJ-64407564 [anti-GPRC5DxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, GPRC5D, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64407564 [anti-GPRC5DxCD3] brings these killer T-cells to the myeloma cell resulting in myeloma cell death.
JNJ-64007957 [anti-BCMAxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, BCMA, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64007957 [anti-BCMAxCD3] brings ...
Protocol No
JANSSEN-64407564MMY1002
AGAVE-201, A Phase 2, open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patient with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at Least 2 lines of Systemic Therapy.
Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease.
Protocol No
SYNDAX-SNDX-6352-0504-CGVHD
Sub Category
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Protocol No
GENMAB-GCT3014-01
Sub Category
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within One Year of Initial Treatment (KarMMa-2)
An Efficacy and Safety Study of bb2121 in Subjects with rrMM and in Subjects with High-risk MM
Protocol No
CELGENE-BB2121-MM-002-KARMMA2
Sub Category
Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplantation in Older Adults
Composite Health Assessment Risk Model (CHARM) for Older Adults
Protocol No
CTN-1704
Sub Category
A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects with Hematological Malignancies
Open-label, multiple-ascending dose study to evaluate the safety, PK, and preliminary clinical activity of KPG-818 as a single agent in adult subjects with selected hematological malignancies, except for multiple myeloma indication. KPG-818 will be used in combination with dexamethasone for dose escalation and dose expansion. The study will consist of 2 parts: Part 1 dose escalation and Part 2 dose expansion.
Protocol No
KANGPU-KPG-818-HEM-101
A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects with Relapsed or Refractory Multiple Myeloma
AEVI-007,in the treatment of relapsed or refractory multiple myeloma.
Protocol No
AEVI-007-MM-101
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy & Safety of Belantamab Mafodotin in Combination with Pomalidomide & Dex (B-Pd) versus Pomalidomide plus Bortezomib & Dex (PVd) in Participants with Relapsed/Refractory Multiple Myeloma
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Protocol No
GSK-207499-DREAMM-08
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIb AL Amyloid
Protocol No
CAELUM-CAEL101-301
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIa AL Amyloid
Protocol No
CAELUM-CAEL101-302
Sub Category
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with or without Renal Insufficiency
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple
Protocol No
IIT-DHAKAL-VICD-MM
Sub Category
A Phase 1 Study to Evaluate the Safety of BB2121 in Subjects with High Risk Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)
A Study to Evaluate the Safety of bb2121 in Subjects with High Risk NDMM (KarMMa4)
Protocol No
CELGENE-BB2121-MM-004-KARMMA4
Sub Category
Mindfulness Meditation and Sleep Disturbance in Hematopoietic Cell Transplant Patients: Inflammatory Mechanisms
Mindfulness meditation and sleep disturbance in hematopoietic cell transplant patients
Protocol No
IIT-KNIGHT-SLEEPHCT
Sub Category
Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1(RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma
RAPA-201 T Cell Therapy for RR MM
Protocol No
RAPA-201-RRMM
Sub Category
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortexomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma
NJ-68284528 a CAR-T directied against BCMA vs PVd or DPd in pt with rr MM (CARTITUDE-4)
Protocol No
JANSSEN-JNJ-68284528-MMY3002
Sub Category